



Attorney Docket No.: UBC.P-031

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gleave et al.  
Serial No.: 10/605,498  
Confirmation: 2497  
Filed: October 2, 2003  
Title: Compositions and methods for treatment of prostate and other cancers

**SUBMISSION OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants request that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith.

No fee is believed to be due with this paper as we have not received an action on the merits. However, the Commissioner is authorized to charge any fees which may be due to Deposit Account Number 15-0610.

Respectfully submitted,

OPPEDAHL & LARSON LLP

*Marina T. Larson*

Marina T. Larson, PhD , Reg. No. 32,038  
P.O. Box 5068  
Dillon, CO 80435-5068  
970-468-6600

---


CERTIFICATE OF MAILING UNDER 37 CFR §1.8(a)

I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on \_\_\_\_\_

April 16, 2004

4-16-2004  
Date of Signature

Lori South  
Lori South



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket Number | UBC.P-031

[illegible][illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/605,498
		Filing Date	10/2/2003
		First Named Inventor	Gleave et al.
		Art Unit	1614
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	UBC.P-031	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DATABASE WPI, Section Ch, Week 199737,1997, Publisher: Derwent Publications Ltd., London, GB, XP002272450	
		GARRIDO ET AL., Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells the Doxorubicin-protecting effect of HSP27, European Journal of Biochemistry, 1996, Page(s) 653-659, Volume 237, Number 3, XP001004835	
		GOTHAM ET AL., Antisense and Sirna Technologies - SMI Conference, IDRUGS, 2003, Page(s) 211-214, Volume 6, Number 3, Publisher: Current Drugs LTD, GB, XP008026723	
		MORINO ET AL., Specific Regulation of HSPs in Human Tumor Cell Lines by Flavonoids, In Vivo - International Journal of In Vivo Research, 1997, Page(s) 265-270, Volume 11, Number 3, XP009007378	
		TAMM ET AL., Antisense therapy in oncology: new hope for an old idea?, Lancet, 2001, Page(s) 489-497, Volume 358, Number 9280, XP004299974	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.